Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Apotex Inc.

www.apotex.com

Latest From Apotex Inc.

Apotex Sees Low Risk Of Coronavirus Supply Interruption

In addition to securing supply for the short term amid the coronavirus pandemic, Apotex is also “actively preparing for longer term scenarios,” as Canada’s largest pharmaceutical manufacturer and API producer.

Manufacturing Sustainability

Don't Assume Your ANDA Will Be Designated, US FDA Tells Aspiring Competitive Generic Therapy Sponsors

Final guidance clarifies that all sponsors who want CGT designation, which can bring exclusivity upon approval, should request it.

Generic Drugs Drug Review

India's SPARC Keeps Paclitaxel Ambition Burning For Now

A US Complete Response Letter for SPARC’s paclitaxel product has cast a cloud over the project’s viability, but the company is still hopeful of an FDA approval by the fourth quarter of fiscal 2021. With the delay in commercialization, investment in some prioritized projects might also require external funding or even an exit from other research assets.

Research & Development Clinical Trials

More Top-Level Pharma Changes In India, Cipla Gets CSO

Top-level personnel movement continues at pharma firms in India, with Cipla now appointing an ex-Amneal executive as its Chief Scientific Officer, while Abbott has effected a rejig at the helm.

India Commercial
See All

Company Information

UsernamePublicRestriction

Register